{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:38:53Z","timestamp":1788349133199,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Severe cutaneous adverse drug reactions (SCARs) are a life\u2010threatening condition. We aimed to identify all carbamazepine\u2010induced SCARs voluntarily reported to the Malaysian pharmacovigilance database and to compare between children and adults. Adverse drug reaction reports for carbamazepine were extracted from 2000 to 2020, and divided into 2 groups, that is, children (aged 0\u201317\u00a0years) and adults (aged 18\u00a0years and above). Age, sex, race, and carbamazepine dose were analyzed using multiple logistic regression. Of 1102 carbamazepine adverse drug reaction reports, 416 reports were SCARs (99 children, 317 adults). Stevens\u2013Johnson syndrome and toxic epidermal necrolysis were the main SCAR types for both age groups. Median time\u2010to\u2010onset for any type of SCAR was 13\u00a0days, regardless of age. In children, Malay individuals were 3.6 times more likely to report SCARs (95% confidence interval, 1.356\u20139.546;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.010) compared to the Chinese population. In adults, carbamazepine\u2010induced SCARs were reported as 3.6 times higher in those with a daily dose of 200 mg or less as compared to a daily dose of 400 mg or more. (95% confidence interval, 2.257\u20135.758;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a0.001) Carbamazepine\u2010induced SCARs reported in Malaysia were predominantly Stevens\u2013Johnson syndrome or toxic epidermal necrolysis, with the majority in Malay individuals. Initiation therapy needs close monitoring between 2\u00a0weeks and 1\u00a0month.\n                  <\/jats:p>","DOI":"10.1002\/jcph.2289","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:36:04Z","timestamp":1686263764000},"page":"1126-1132","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Carbamazepine\u2010Induced Severe Cutaneous Adverse Drug Reactions: A 21\u2010Year Comparison Between Children and Adults in Malaysia"],"prefix":"10.1002","volume":"63","author":[{"given":"Vidhya","family":"Hariraj","sequence":"first","affiliation":[{"name":"National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Kee","family":"Wo","sequence":"additional","affiliation":[{"name":"National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing Chet","family":"Lee","sequence":"additional","affiliation":[{"name":"National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azuana","family":"Ramli","sequence":"additional","affiliation":[{"name":"National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199106020-00005"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.74963"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.839"},{"key":"e_1_2_10_6_1","unstructured":"National Pharmaceutical Regulatory Agency.Annual Report National Centre for Adverse Drug Reaction Monitoring 2017. National Pharmaceutical Regulatory Agency Ministry of Health;2017. Accessed August 29 2022.https:\/\/www.npra.gov.my\/easyarticles\/images\/users\/1108\/Annual%20Report\/AR2017.pdf"},{"key":"e_1_2_10_7_1","unstructured":"World Health Organization\u2013Uppsala Monitoring Centre (WHO\u2010UMC). VigiLyze. Accessed August 29 2022.https:\/\/vigilyze.who\u2010umc.org\/"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2013.02.003"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3322"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250049006"},{"key":"e_1_2_10_11_1","unstructured":"World Health Organization\u2010Uppsala Monitoring Centre (WHO\u2010UMC). The use of the WHO\u2010UMC system for standardised case causality assessment;2005. Accessed August 29 2022.https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf"},{"key":"e_1_2_10_12_1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). EMA\/873138\/2011 Rev 2.2017. Accessed April 29 2023.https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010module\u2010vi\u2010collection\u2010management\u2010submission\u2010reports_en.pdf"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2015.5.2.68"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304767"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70298-3"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4201357"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0039-z"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2012.07.010"},{"key":"e_1_2_10_19_1","first-page":"15","article-title":"Association of HLA\u2010B*1502 allele and carbamazepine\u2010induced severe adverse cutaneous drug reaction among Asians, a review","volume":"13","author":"Lim KS","year":"2008","journal-title":"Neurol Asia"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04745.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4114"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15498"},{"key":"e_1_2_10_23_1","first-page":"11","article-title":"Usage pattern of carbamazepine and associated severe cutaneous adverse reactions in singapore following implementation of HLA\u2010B*15:02 genotyping as standard\u2010of\u2010care","author":"Sung C","year":"2020","journal-title":"Front Pharmacol"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001034"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2040"},{"key":"e_1_2_10_27_1","unstructured":"Malaysian Society of Neurosciences. (2017). Concensus Guidelines on the Management of Epilepsy. Accessed April 29 2023.\u00a0https:\/\/www.neuro.org.my\/assets\/guideline\/2017Epilepsy.pdf"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.528"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:22:01Z","timestamp":1694308921000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/jcph.2289"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2289","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"2023-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}